Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Lung Neoplasms
  • Protein Kinase Inhibitors
  • Quinazolines
  • Receptor, Epidermal Growth Factor

abstract

  • Recurrence of EGFR-mutant lung cancer after stopping adjuvant TKI should not preclude a trial of TKI retreatment; a phase II trial of erlotinib in this setting is underway. Studies of adjuvant EGFR-TKI will underestimate the potential survival benefit of adjuvant TKI for patients with EGFR-mutant lung cancers if retreatment at recurrence is not given.

publication date

  • October 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3186869

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-11-1080

PubMed ID

  • 21831955

Additional Document Info

start page

  • 6322

end page

  • 8

volume

  • 17

number

  • 19